Research Development and Commercialization

The mission of the Office of Research Development & Commercialization, at the University of North Texas Health Science Center is to assist UNTHSC, its researchers, and its community with the development, promotion, and commercialization of technologies.

“How CPRIT Supports Companies to Accelerate
the Progression of the Development of New Cancer Drugs, Diagnostics, and Therapies”

Presented by:

Mike Lang Mike Lang
Chief Product Development Research Officer

Thursday, December 8th,2016
AM to 10:00 AM

1000 Montgomery Fort Worth, TX
Medical Education and Training Building
MET-125S – South Auditorium



On December 8th, you can meet Mike Lang who will speak about how CPRIT has changed the face of research and innovation in Texas and how your company can benefit from partnering with CPRIT for funding to take your company to the next level.  Mike will also share his experience on what constitutes the best “pitch” presentation to gain the attention of potential investors.
Texas voters overwhelmingly approved a constitutional amendment in 2007 establishing the Cancer Prevention and Research Institute of Texas (CPRIT) and authorizing the state to issue $3 billion in bonds to fund groundbreaking cancer research and prevention programs and services in Texas.  CPRIT’s goal is to expedite innovation in cancer research and product development, and to enhance access to evidence-based prevention programs throughout the state.  Under the guidance of its governing body, the Oversight Committee, CPRIT accepts applications and awards grants for a wide variety of cancer-related research and for the delivery of cancer prevention programs and services by public and private entities located in Texas. All CPRIT-funded research will be conducted in state by Texas-based scientists and reflect CPRIT’s mission to attract and expand the state’s research capabilities and create high quality new jobs in Texas.     

Mr. Lang leads CPRIT’s product development research program, designed to accelerate the progression of new cancer drugs, diagnostics, and therapies from the laboratory into clinical practice. His multi-state experience includes founding and serving as chief executive officer of a cancer diagnostic company, serial entrepreneurship, and managing a portfolio for an early stage investment.Prior to joining CPRIT in November 2015, Mr. Lang was the founder and CEO of NanoVision, a cancer diagnostics company. He headed business development at the venture capital-funded wound healing company Gilatech, where he led its novel biomaterial therapy. Mr. Lang oversaw a company restructuring as president of Dallas-based Galt Medical, served as a product manager at Johnson & Johnson, and was vice president of business development at BioEnterprise, where he directed the startup and growth of early stage firms.Mr. Lang has a bachelor’s in biomedical engineering from Northern Arizona University and a master’s in business administration from Arizona State University.  



This page was last modified on November 9, 2016